EPAS1 and cancer: The latter is of particular interest given that it has been reported that HIF-1α and HIF-2α may have opposing roles on the progress of cancer.98 In this regard the development of inhibitors, including those not binding to the active site metal, that exploit differences in the binding of different HIF-α and non-HIF substrates to the PHDs is also of interest.